Cover Image
市場調查報告書

植物性醫藥品·植物萃取醫藥品:全球市場

Botanical and Plant-Derived Drugs: Global Markets

出版商 BCC Research 商品編碼 82886
出版日期 內容資訊 英文 175 pages
訂單完成後即時交付
價格
Back to Top
植物性醫藥品·植物萃取醫藥品:全球市場 Botanical and Plant-Derived Drugs: Global Markets
出版日期: 2017年11月27日 內容資訊: 英文 175 pages
簡介

全球植物性醫藥品·植物萃取醫藥品的市場規模,預測在2017年到2022年間將以6.1%的年複合成長率 (CAGR) 擴大,從2017年的294億美元到2022年成長到396億美元。

本報告提供全球植物性醫藥品·植物萃取醫藥品市場相關調查,提供植物性醫藥品產業概要,世界市場趨勢分析與年複合成長率預測,處方藥,產業結構·競爭情形·市場成長的促進要素分析,包含治療領域·各地區的銷售額分析的市場規模·區分相關議論,並彙整植物性醫藥品·植物萃取醫藥品產業的未來展望等相關資訊。

第1章 簡介

第2章 摘要·亮點

第3章 市場·技術背景

  • 植物萃取醫藥品的簡歷
  • 未來的機會
  • 入門
  • 主要的促進要素
  • 主要課題
  • 美國政府的投資
  • 產業投資趨勢
  • 實例分析:NUTRITION SCIENCE PARTNERS LTD. (NESTLE HEALTH)
  • 植物性醫藥品定義
  • 法規流程的理解
  • 研究性新藥申請
    • 臨床試驗
    • 新藥的申請
  • 第一和第二批美國植物藥
  • 候補開發平台的植物性醫藥品
  • 開發平台的成長
  • 整體醫藥品形勢
  • 植物性醫藥品的主要分類
  • 智慧財產權
  • 生產
  • 新的生產類型:植物性醫藥品
  • 醫藥品的開發與製造

第4章 市場區隔:各技術類型

  • 植物萃取醫藥品銷售:各技術
  • 植物萃取醫藥品:各治療領域
  • 植物萃取醫藥品的規模:各治療領域
  • 開發平台的展望:臨床開發的植物性醫藥品的結構

第5章 新發展與市場機會

  • 荷爾蒙療法與代謝
  • 感染疾病用途
  • 疼痛及中樞神經系統疾病用途
  • 心血管及代謝性疾病用途
  • 呼吸系統,發炎性,自體免疫疾病用途
  • 皮膚病用途
  • 腸胃系統用途
  • 癌症用途
  • 臨床開發的植物性醫藥品

第6章 企業簡介

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO022H

Report Highlights

The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.

Report Includes:

  • 27 tables
  • An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
  • Examination of the industry structure, competition, and market drivers
  • Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry

Report Scope

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The study also does not cover the following:

  • Underground or illicit drugs.
  • Home remedies.
  • Tribal medicines.
  • Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
  • Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
  • Intravenously delivered nutrients of plant origin, such as dextrose.
  • Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
  • Plant substances serving in cosmetics, toiletries and personal care products.
  • Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
  • Marine life.

The format of the study is organized around the following topics:

  • Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
  • Industry structure.
  • Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
  • Market drivers.
  • Market projections through 2022.
  • Competition.
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Analyst Credentials

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Trends and Drivers for Botanical Drug Development

Chapter 3: Market and Technology Background

  • Brief History of Plant-Derived Medicines
  • Opportunity Lies Beyond What Is Known
  • Getting Started
  • Key Drivers
  • Key Challenges
  • U.S. Government Investment
  • Industry Investment
  • Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
  • Botanical Drugs Defined
  • Understanding the Regulatory Process
  • Investigational New Drug Applications
    • Clinical Trials
    • New Drug Application
  • The First and Second U.S. Approved Botanical Drug
    • Veregen (Chinese Green Tea Catechins)
    • Mytesi, Formerly Fulyzaq (Crofelemer)
  • Botanical Candidates in the Pipeline
    • Samital
    • Danshen Dripping Pill (Cardiotonic Pill)
    • EISO (East Indian Sandalwood Oil)
    • Microbio and WH-1, MB-6 and OB318
  • A Growing Pipeline
  • Overall Pharma Landscape
  • Major Classes of Plant Drugs
    • Terpenes and Steroids
    • Alkaloids and Glycosides
    • Phenols
    • Proanthocyanidins
    • The Emergence of Cannabinoids
  • Intellectual Property
  • Production
  • A New Type of Production: Plant-Made Drugs
    • Moving Production Forward
    • Supply and Legal Issues
  • Drug Development and Manufacture

Chapter 4: Market Breakdown by Technology Type

  • Sales of Plant-derived Drugs by Region
  • Plant-derived Drugs by Therapeutic Area
  • Value of Plant-derived Drugs by Therapeutic Area
  • A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development

Chapter 5: New Developments and Market Opportunities

  • Hormone Therapy and Metabolism Applications
  • Infectious Disease Applications
  • Pain and Central Nervous System Disease Applications
  • Cardiovascular and Metabolic Applications
  • Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
  • Dermatology Applications
  • Gastrointestinal Applications
  • Oncology Applications
  • Botanical Drugs in Clinical Development
    • Promising Candidates for Botanical Drugs

Chapter 6: Company Profiles

Chapter 7: Appendix

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Botanical and Plant-derived Drugs*, by Type, Through 2022 ($ Millions)
    • Table 1: Key Events Related to Botanical Medicine
    • Table 2: Notable Plant-derived Drugs
    • Table 3: Number of Botanicals Pre-INDS and INDs Submitted to the FDA, by Type, Through 2013 (Units)
    • Table 4: SWOT Analysis of Botanical Drug Development
    • Table 5: Key Investments in Botanical and Other Plant-derived Drugs
    • Table 6: Distinctions Among Products That Use Plants Medicinally
    • Table 7: Botanical Composition of Menerba (MF 101)*
    • Table 8: Top Pharma Companies, by Revenue, 2016 ($ Billions)
    • Table 9: Major Upcoming U.S. Patent Expiries, 2014-2022
    • Table 10: Major Producers of Raw Materials for Plant-Based Medicine
    • Table 11: Key Companies with Natural Product Libraries
    • Table 12: Number of FDA-Approved Botanical Drugs, Through 2022
    • Table 13: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, Through 2022 ($ Millions)
    • Table 14: Plant-derived Hormone Therapy and Metabolism Drugs in Late-Stage Development
    • Table 15: Plant-derived Infectious Disease Drugs in Late-Stage Development
    • Table 16: Brain Disorders That are Refractory to Small Molecule Drugs
    • Table 17: Plant-derived Pain and CNS Drugs in Late-Stage Development
    • Table 18: Plant-derived Cardiovascular and Metabolic Drugs in Late-Stage Development
    • Table 19: Plant-Derived Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Drugs in Late-Stage Development
    • Table 20: Plant-derived Dermatology/Wound Care Drugs in Late-Stage Development
    • Table 21: Plant-derived Gastrointestinal Drugs in Late-Stage Development
    • Table 22: Estimated U.S. New Cancer Cases, by Gender, 2016
    • Table 23: Plant-derived Oncology Drugs in Late-Stage Development
    • Table 24: Botanical Drugs in Clinical Development with Possible FDA-Approved Commercialization, Through 2022
    • Table 25: Promising Compounds Being Studied for Medicinal/Therapeutic Potential
    • Table 26: Plant-derived Drugs: Their Origin and Actions
    • Table 27: Useful Resources for the Botanical Industry

List of Figures

  • Summary Figure: Global Market for Botanical and Plant-derived Drugs*, by Type, 2016-2022 ($ Millions)
    • Figure 1: Top Therapeutic Areas of FDA Drug Approvals, 2016 (Number, Total = 22)
    • Figure 2: Composition of FDA-Approved Botanical Indications, by Therapeutic Area, 2017 and 2022 (No./%)
    • Figure 3: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, 2017 and 2022 ($ Millions)
    • Figure 4: Therapeutic Areas Targeted for Botanical Drugs in Phase 2 or Later, 2017* (%)
Back to Top